by José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz
Borrego, Agostina Stradella, Begoña Bermejo, Peter Schmid, Frederik Marmé,
Santiago Escrivá-de-Romani, Lourdes Calvo, Nuria Ribelles, Noelia Martinez,
Cinta Albacar, Aleix Prat, Florence Dalenc, Khaldoun Kerrou, Marco Colleoni,
Noemia Afonso, Serena Di Cosimo, Miguel Sampayo-Cordero, Andrea Malfettone,
Javier Cortés, Antonio Llombart-Cussac, PHERGain steering committee and trial
investigators
The Lancet
Oncology: VOLUME 22,
ISSUE 6, P858-871, JUNE 01, 2021
18F-FDG-PET identified patients with HER2-positive,
early-stage breast cancer who were likely to benefit from chemotherapy-free
dual HER2 blockade with trastuzumab and pertuzumab, and a reduced impact on
global health status. Depending on the forthcoming results for the 3-year
invasive disease-free survival endpoint, this strategy might be a valid
approach to select patients not requiring chemotherapy.
